Management of dyslipidemia after allogeneic hematopoietic stem cell transplantation

被引：0
|
作者：
Yingxue Lu
Xiaojing Ma
Jie Pan
Rongqiang Ma
Yujie Jiang
机构：
[1] Shandong Provincial Hospital Affiliated to Shandong First Medical University,Department of Cardiology
[2] Shandong Provincial Hospital Affiliated to Shandong First Medical University,Department of Hematology
[3] Shandong Provincial Hospital Affiliated to Shandong First Medical University,undefined
来源：
Lipids in Health and Disease | / 21卷
关键词：
Allogeneic hematopoietic stem cell transplantation; Dyslipidemia; Graft-versus-host disease; Statins; Proprotein convertase subtilisin/Kexin type 9 (PCSK9);
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Dyslipidemia is one of the complications after allogeneic hematopoietic stem cell transplantation (allo-HSCT), and it is often underestimated and undertreated. Dyslipidemia in allo-HSCT recipients has been confirmed to be associated with endocrine dysfunction, acute and chronic graft-versus-host disease (aGVHD and cGVHD), immunosuppressive agent application, etc. However, few studies have illustrated the accurate molecular signaling pathways involved in dyslipidemia, and there are no standard guidelines for dyslipidemia management after HSCT. This review will discuss the pathogenesis of dyslipidemia, especially the association with aGVHD and/or cGVHD. Comprehensive treatment methods for dyslipidemia after HSCT will also be summarized.
引用
收藏
相关论文
共 50 条
  • [41] Epileptic Seizures After Allogeneic Hematopoietic Stem Cell Transplantation
    Wang, Zhuo
    Zhao, Munan
    Gao, Sujun
    FRONTIERS IN NEUROLOGY, 2021, 12
  • [42] Visceral leishmaniasis after allogeneic hematopoietic stem cell transplantation
    H J Agteresch
    M B van 't Veer
    J J Cornelissen
    J F Sluiters
    Bone Marrow Transplantation, 2007, 40 : 391 - 393
  • [43] Allogeneic hematopoietic stem cell transplantation
    Faul, C.
    ONKOLOGIE, 2012, 35 : 112 - 112
  • [44] Allogeneic hematopoietic stem cell transplantation
    Kai, S
    Hara, T
    THERAPEUTIC APHERESIS AND DIALYSIS, 2003, 7 (03) : 285 - 291
  • [45] Adoptive immunotherapy ± Ruxolitinib and second allogeneic hematopoietic stem cell transplantation in patients with relapsed Myelofibrosis after allogeneic hematopoietic stem cell transplantation
    Bogdanov, R.
    Ditschkowski, M.
    Steckel, N. -K.
    Klisanin, V.
    Kordelas, L.
    Trenschel, R.
    Beelen, D. W.
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 60 - 61
  • [46] Lung Transplantation for Bronchiolitis Obliterans after Allogeneic Hematopoietic Stem Cell Transplantation
    Kim, Yu Ri
    Haam, Seok Jin
    Park, Yoon Ghil
    Lim, Beom Jin
    Park, Yoo Mi
    Paik, Hyo Chae
    YONSEI MEDICAL JOURNAL, 2012, 53 (05) : 1054 - 1057
  • [47] Dermatology consultation and change in diagnosis and/or management of patients after allogeneic hematopoietic stem cell transplantation
    Champlain, Amanda
    Bach, Daniel
    West, Dennis
    Mehta, Jayesh
    Cotliar, Jonathan
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2014, 70 (05) : AB115 - AB115
  • [48] Toxoplasmosis after allogeneic hematopoietic stem cell transplantation: Impact of serostatus-based management
    Amikura, Takahito
    Kikuchi, Taku
    Kato, Jun
    Koda, Yuya
    Sakurai, Masatoshi
    Yamazaki, Rie
    Mikita, Kei
    Saburi, Masuho
    Nakazato, Tomonori
    Mori, Takehiko
    TRANSPLANT INFECTIOUS DISEASE, 2021, 23 (03)
  • [49] Management of fulminant botulism after allogeneic hematopoietic cell transplantation
    Takasugi, Nao
    Uchida, Kaname
    Shimoda, Konomi
    Watanabe, Eiichiro
    Kato, Shota
    Hiwatari, Mitsuteru
    Ikeda, Mahoko
    Kato, Motohiro
    Matsui, Hikoro
    PEDIATRIC BLOOD & CANCER, 2024,
  • [50] Management of Hepatitis B Virus in Allogeneic Hematopoietic Stem Cell Transplantation
    Wu, Yibo
    Huang, He
    Luo, Yi
    FRONTIERS IN IMMUNOLOGY, 2021, 11
12345